184
Views
12
CrossRef citations to date
0
Altmetric
Review

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

, , , &
Pages 43-48 | Published online: 27 Sep 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Seref Gul, Onur Ozcan, Sinan Asar, Alper Okyar, Ibrahim Barıs & Ibrahim Halil Kavakli. (2021) In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. Journal of Biomolecular Structure and Dynamics 39:17, pages 6772-6791.
Read now
Maliheh Safavi, Alireza Foroumadi & Mohammad Abdollahi. (2013) The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opinion on Drug Discovery 8:11, pages 1339-1363.
Read now

Articles from other publishers (10)

Md. Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md. Sohanur Rahman, Fouad Damiri, Mohammed Berrada & Md. Habibur Rahman. (2022) Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus. Environmental Science and Pollution Research 29:31, pages 46385-46404.
Crossref
Gabriela Tavares, Fatima. O. Martins, Bernardete. F. Melo, Paulo Matafome & Silvia. V. Conde. (2021) Peripheral Dopamine Directly Acts on Insulin-Sensitive Tissues to Regulate Insulin Signaling and Metabolic Function. Frontiers in Pharmacology 12.
Crossref
Robert Krysiak & Bogusław Okopien. (2015) Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels. Basic & Clinical Pharmacology & Toxicology 116:3, pages 251-256.
Crossref
A. P. Athanasoulia, C. Sievers, M. Uhr, M. Ising, G. K. Stalla & H. J. Schneider. (2013) The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas. Pituitary 17:3, pages 240-245.
Crossref
Andrew M. Beekman & Russell A. Barrow. (2014) Fungal Metabolites as Pharmaceuticals. Australian Journal of Chemistry 67:6, pages 827.
Crossref
Stefan Amisten, Albert Salehi, Patrik Rorsman, Peter M. Jones & Shanta J. Persaud. (2013) An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacology & Therapeutics 139:3, pages 359-391.
Crossref
Rajib Mukherjee & Jong Won Yun. (2012) Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on α2-adrenergic receptor in 3T3-L1 adipocyte cells. Molecular Biology Reports 40:5, pages 3783-3792.
Crossref
Ana B. Bueno, Ana M. Castaño & Ángel Rodríguez. 2013. Drug Discovery. Drug Discovery 205 243 .
Susan L. McElroy & Paul E. KeckJrJr. (2012) Obesity in Bipolar Disorder: An Overview. Current Psychiatry Reports 14:6, pages 650-658.
Crossref
C. D. Gibson, W. Karmally, D. J. McMahon, S. L. Wardlaw & J. Korner. (2012) Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes, Obesity and Metabolism 14:4, pages 335-340.
Crossref